Pacira Seeks Support for Three Nominees to Execute 5x30 Growth Strategy at June 9 Meeting
Pacira BioSciences sent a May 12 letter urging shareholders to vote at the June 9 Annual Meeting for its three board nominees to support its 5x30 growth plan. It cites nominees’ expertise in leadership, M&A, R&D and manufacturing and labels DOMA Perpetual’s slate underqualified.
1. Shareholder Letter and Voting Timeline
Pacira BioSciences dispatched a letter to stockholders on May 12, highlighting the June 9 Annual Meeting and reminding record holders as of April 22 to vote using the BLUE proxy card for its three director nominees.
2. Progress of 5x30 Strategy
The board underscores progress on its 5x30 strategic plan, which targets fivefold growth by 2030, citing robust execution in R&D, commercialization, manufacturing and supply chain initiatives; the company reports 17 meetings with DOMA since September 2023 without substantive alternative proposals.
3. Board Nominee Qualifications vs Activist Slate
Pacira profiles its nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—as possessing deep expertise in government affairs, clinical development and operations, and contrasts them with DOMA Perpetual’s candidates, which lack public board and biopharmaceutical experience.